@MK2forU Marcus Kuehne aka Huggenberg

Marcus Kuehne aka Huggenberg posts on X about $ibrx, investment, ai, alc the most. They currently have [---] followers and [--] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

• [--] Week [---] -93%
• [--] Month [------] +116%
• [--] Months [-------] +1,030%
• [--] Year [-------] +142,598%

Mentions: [--] #

• [--] Week [--] +7.10%
• [--] Month [--] +86%
• [--] Months [--] +192%
• [--] Year [--] +4,700%

Followers: [---] #

• [--] Week [---] +6.80%
• [--] Month [---] +26%
• [--] Months [---] +209%
• [--] Year [---] +143%

CreatorRank: [---------] #

Social Influence

Social category influence finance 7.61% stocks 2.17% technology brands 2.17% countries 2.17% automotive brands 1.09% cryptocurrencies 1.09% celebrities 1.09%

Social topic influence $ibrx #16, investment 6.52%, ai 5.43%, alc 4.35%, the face 3.26%, $nwbo 3.26%, link 2.17%, in the 2.17%, platform 2.17%, protocol 2.17%

Top accounts mentioned or mentioned by @immunitybio @drpatsoonshiong @gretchmick @drpatrick @daviddin @urodocash @mdandersonnews @drmakaryfda @cmsgov @deanjc420 @envitamedical @beonemedicines @drjbhattacharya @seckennedy @robertkennedyjr @joerogan @elonmusk @drozcms @drpatsoonshiongs @nanthealth

Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX) Tesla, Inc. (TSLA) One Cash (ONC)

Top Social Posts

Top posts by engagements in the last [--] hours

"Link to JP Morgans webcast from $IBRX website: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317878-immunitybio-inc/webcastgpu_only=true&kiosk=true https://jpmorgan.metameetings.net/events/healthcare26/sessions/317878-immunitybio-inc/webcastgpu_only=true&kiosk=true"
X Link 2026-01-16T17:28Z [---] followers, [----] engagements

"VivaBiocell a 100%-owned $IBRX subsidiary will be a partner in a trial for triple-negative breast cancer (TNBC). The NANT apheresis Bioreactor will be used to produce autologous Hybrid cells (aHyC) from the patients dendritic and cancer cells. https://www.ita-slo.eu/en/news-and-events/events/press-release-dated-19-december-2025#::text=VivaBioCell%2C%20the%20University%20Hospital&text=In%20addition%20to%20preparations%20for%20delivering%20treatment%20with%20the%20advanced%20cellular%20therapy%20aHyC%2DTNBC"
X Link 2026-01-29T14:39Z [---] followers, [----] engagements

"$IBRX Besides the VivaBiocell small-scale bioreactors Soon-Shiong described an new generation of automated AI-assisted cell-therapy manufacturing systems designed to take a blood sample expand NK and other cells. Take a look at the apheresis platform: https://cloud.hoststar.ch/s/AZttTSkwAWLpmYQ Revealed at our summit: building and teaching with machine vision and AI the worlds first robot to manufacture NK cells at scaleWill be installed in next [--] months and then we change the cost of cell therapy forever to make it available to so many who need immune restoration https://t.co/Qc6Mfd0c8g"
X Link 2026-01-29T14:45Z [---] followers, [----] engagements

"$IBRX More patients deserve this miraculous remission. Remarkable results from Dr. Patrick Soon-Shiong's Anktiva 1-person trial for a type of non-Hodgkin lymphoma called Waldenstrm's macroglobulinemia. The patient has been in complete remission for [--] months. So ill was the patient that cancer had replaced [--] percent of bone-marrow Remarkable results from Dr. Patrick Soon-Shiong's Anktiva 1-person trial for a type of non-Hodgkin lymphoma called Waldenstrm's macroglobulinemia. The patient has been in complete remission for [--] months. So ill was the patient that cancer had replaced [--] percent"
X Link 2026-01-29T19:36Z [---] followers, [----] engagements

"$IBRX Additional Information about Anktiva in the Long Covid INTERRUPT_LC trial. https://polybio.org/polybio-adds-key-resources-to-long-covid-immunotherapy-pilot-trial-analysis/ Will ImmunityBio $IBRX be a game-changer for Long COVID Dr. Patrick Soon-Shiong presented clinical data on Bioshield. Beyond remission in cancer patients two clinical trials are underway to eliminate persistent virus from the bodies of Long COVID patients. [--]. Bioshield https://t.co/7z0cdjFQEI https://polybio.org/polybio-adds-key-resources-to-long-covid-immunotherapy-pilot-trial-analysis/ Will ImmunityBio $IBRX be a"
X Link 2026-02-01T12:24Z [---] followers, [----] engagements

"$IBRX Dr. Dino Prato a pioneer in precision personalized medicine at @EnvitaMedical with [--] years of experience in immunotherapy explains the science behind Anktiva. A must-watch https://www.youtube.com/watchv=5QYPW3edX28 https://www.youtube.com/watchv=5QYPW3edX28"
X Link 2026-02-03T08:39Z [---] followers, [----] engagements

"$IBRX Why are lymphocytes often neglected in cancer treatment and what changes are necessary https://huggenberg.substack.com/p/fundamentals-of-immunotherapy-20 https://huggenberg.substack.com/p/fundamentals-of-immunotherapy-20"
X Link 2026-02-09T12:45Z [---] followers, [----] engagements

"$IBRX I previously compiled an overview of companies involved in IT and AI related to Cancer Bioshield. https://x.com/MK2forU/status/2009602165418102921 I've put together a comprehensive map of the $IBRX network @DrPatrick has built. It looks like fixing cancer is just the tip of the iceberg. He's built the plumbing for the most advanced medical system in the world. This is giving Tesla [----] before the multi-year rerating. https://t.co/lMLJ7z2uGT https://x.com/MK2forU/status/2009602165418102921 I've put together a comprehensive map of the $IBRX network @DrPatrick has built. It looks like"
X Link 2026-02-09T14:09Z [---] followers, [----] engagements

"$IBRX A comprehensive step-by-step summary of the key steps in Immunotherapy [---] highlighting the vital role of Anktiva in transforming standard cancer therapies. https://huggenberg.substack.com/p/fundamentals-of-immunotherapy-20 https://huggenberg.substack.com/p/fundamentals-of-immunotherapy-20"
X Link 2026-02-10T20:08Z [---] followers, [----] engagements

"$IBRX This meeting is an extension of the outcomes of the U.S.-Saudi Biotech Alliance Summit held in San Francisco enhancing pathways for scientific and investment cooperation supporting knowledge transfer and innovation localization and opening new horizons to strengthen partnership in the field of biotechnology. () #. https://t.co/ot9BujALFn () #. https://t.co/ot9BujALFn"
X Link 2026-02-16T14:45Z [---] followers, [----] engagements

"Members of the party boycotted President Volodymyr Zelensky's speech to the Swiss parliament on June [--] claiming it violated the country's tradition of neutrality"
X Link 2023-10-23T18:26Z [--] followers, [--] engagements

"Trump supporters freak out"
X Link 2024-05-31T07:06Z [--] followers, [--] engagements

"$IBRX Addressing BCG supply shortages workflow and enhancing #BladderCancer treatment through strategic partnerships. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss the current status and use of #Anktiva https://t.co/581fkw4kdm https://t.co/1VshRYT2UI Addressing BCG supply shortages workflow and enhancing #BladderCancer treatment through strategic partnerships. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss the current status and use of #Anktiva https://t.co/581fkw4kdm https://t.co/1VshRYT2UI"
X Link 2024-09-27T19:48Z [---] followers, [--] engagements

"$IBRX Complete response to multimodal temporal therapy in adv pancreatic cancer provides proof-of-concept for the Nant Cancer Vaccine: tumor-targeted chemotherapy + IL-15 superagonist Anktiva & natural killer cell immunotherapy to induce immunogenic cell death. https://t.co/lMsxMfUJ3q https://t.co/b73ly3FvBG Complete response to multimodal temporal therapy in adv pancreatic cancer provides proof-of-concept for the Nant Cancer Vaccine: tumor-targeted chemotherapy + IL-15 superagonist Anktiva & natural killer cell immunotherapy to induce immunogenic cell death. https://t.co/lMsxMfUJ3q"
X Link 2025-05-29T13:45Z [--] followers, [--] engagements

"ImmunityBio's Car-NK strategy After AI research a potential strategy for ImmunityBio's future NK-92 and CAR-NK platform can be inferred from various clues provided by three AACR25 abstract posters. $IBRX @ImmunityBio #Immunotherapy #CARNK #NKCell Details: https://cloud.hoststar.ch/s/FG546bHA6wgj9TA https://cloud.hoststar.ch/s/FG546bHA6wgj9TA"
X Link 2025-06-15T20:01Z [--] followers, [----] engagements

"@ImmunityBio Bioshield (lymphocyte restoration) would be an ideal match to achieve further enhancements of @BeOneMedicines BCL2xCDK9 dual degrader in chronic lymphocytic leukemia (CLL) and they already have a collaboration for Tislelizumab and Anktiva in NSCLC. $IBRX $ONC Despite progress in CLL and related malignancies many patients relapse or develop resistance with few options left. At #EHA2025 our oral presentations show how novel assets and combination strategies aim to overcome resistance and expand possibilities for patients with https://t.co/t3ifzsk7w9 Despite progress in CLL and"
X Link 2025-06-23T14:48Z [--] followers, [---] engagements

"$IBRX Anktiva is approved in the UK https://www.gov.uk/government/news/mhra-approves-nogapendekin-alfa-inbakicept-to-treat-adult-patients-with-non-muscle-invasive-bladder-cancer https://www.gov.uk/government/news/mhra-approves-nogapendekin-alfa-inbakicept-to-treat-adult-patients-with-non-muscle-invasive-bladder-cancer"
X Link 2025-07-04T15:09Z [--] followers, [---] engagements

"$IBRX Wonderful attitude and good luck in the third round.👏👍👊 I did it I've run this 4th of July [--] mile race forever. Not going to let cancer treatment make me sit it out I practiced last week to make sure I could go [--] and today I ran it w one of my gym besties [--] more days until I start round [--] of BIOSHIELD w @ImmunityBio I'm halfway. 👊🏼 https://t.co/RZ9kwZGtZr I did it I've run this 4th of July [--] mile race forever. Not going to let cancer treatment make me sit it out I practiced last week to make sure I could go [--] and today I ran it w one of my gym besties [--] more days until I start"
X Link 2025-07-04T18:39Z [--] followers, [---] engagements

"$IBRX ResQ117EX-ALC as the first Lymphopenia trial: First Anktiva trial for early-stage cancer. First Anktiva trial that is not limited to late-stage cancer where the immune system is already compromised by chemotherapy and radiation which can hinder Anktiva's effectiveness"
X Link 2025-07-09T15:52Z [--] followers, [---] engagements

"$IBRX ResQ117EX-ALC Lymphopenia trial: No specific cancer type is mentioned; all types are eligible to participate in the trial. This makes it the first universal Anktiva trial. It is also the first trial involving non-metastatic minimally treated patients receiving Anktiva"
X Link 2025-07-09T15:54Z [--] followers, [----] engagements

"$IBRX ResQ117EX-ALC Lymphopenia trial: Absolute Lymphocyte Count is a proven and inexpensive biomarker accessible to everyone. Eligibility criteria are: - ALC [----] before first-line treatment - or ALC [----] during or after progression following first-line therapy"
X Link 2025-07-09T16:03Z [--] followers, [---] engagements

"$IBRX Good morning please send a message to @DrMakaryFDA @DrJBhattacharya @SecKennedy @RobertKennedyJr @joerogan to help @DrPatSoonShiong to be able to present Bioshield/Anktiva. You don't need to be a physician to save someone's life today. Please help and pass this message Thank https://t.co/0hIFRauA6A Good morning please send a message to @DrMakaryFDA @DrJBhattacharya @SecKennedy @RobertKennedyJr @joerogan to help @DrPatSoonShiong to be able to present Bioshield/Anktiva. You don't need to be a physician to save someone's life today. Please help and pass this message Thank"
X Link 2025-07-12T15:00Z [--] followers, [---] engagements

"$IBRX The next Cancer Therapy. Great explanation of @GretchMick on her #Bioshield therapy. - Targeting: CEA adenovirus vaccine (Tri-Ad5) targets NK cells to the tumor. - Stimulation: Anktiva stimulates NK- T- and memory T-cells. - Less harm to NK-cells : Chemo Capecitabine BIOSHIELD vs Immunotherapy #cancer #coloncancer #coloncancersigns #immunotherapy #bioshield #immunitybio #chemo #xeloda #capecitabine #capox #cancerdecoded https://t.co/cPGzLltQWW BIOSHIELD vs Immunotherapy #cancer #coloncancer #coloncancersigns #immunotherapy #bioshield #immunitybio #chemo #xeloda #capecitabine #capox"
X Link 2025-07-12T16:33Z [--] followers, [----] engagements

"$IBRX Somebody else told you so Japan's most senior oncologist Professor Fukushima continues to slam the mRNA genetic vaccines. "Until now vaccines were proteins and when injected here they didnt go elsewhere so easily. But the moment they were put into nanoparticles they enter the bloodstream and go https://t.co/Kdn5Lh7o5J Japan's most senior oncologist Professor Fukushima continues to slam the mRNA genetic vaccines. "Until now vaccines were proteins and when injected here they didnt go elsewhere so easily. But the moment they were put into nanoparticles they enter the bloodstream and go"
X Link 2025-07-15T18:10Z [--] followers, [---] engagements

"$IBRX Protecting immune cells before radiation in #ProstateCancer treatment. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care https://t.co/ffQch9elni Protecting immune cells before radiation in #ProstateCancer treatment. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care https://t.co/ffQch9elni"
X Link 2025-07-22T04:45Z [--] followers, [---] engagements

"The Bioshield strategy is explained briefly and clearly. @ImmunityBio $IBRX https://www.youtube.com/watchv=2G1ntNhSDCY https://www.youtube.com/watchv=2G1ntNhSDCY"
X Link 2025-07-24T13:01Z [--] followers, [---] engagements

"$IBRX Bladder Cancer: Duration matters"
X Link 2025-07-24T14:39Z [--] followers, [----] engagements

"@DavidDin Here is the AI-generated comparison of therapies for BCG-Unresponsive NMIBC for CIS $IBRX @MK2forU This graphic is quite good. One should start producing easy graphics that show to everyday people how much better Anktiva is compared to the current leading drugs. @MK2forU This graphic is quite good. One should start producing easy graphics that show to everyday people how much better Anktiva is compared to the current leading drugs"
X Link 2025-07-26T14:46Z [--] followers, [---] engagements

"@DavidDin And here is the AI-generated comparison of therapies for BCG-Unresponsive NMIBC for Papillary $IBRX @MK2forU This graphic is quite good. One should start producing easy graphics that show to everyday people how much better Anktiva is compared to the current leading drugs. @MK2forU This graphic is quite good. One should start producing easy graphics that show to everyday people how much better Anktiva is compared to the current leading drugs"
X Link 2025-07-26T14:49Z [--] followers, [---] engagements

"@DrPatSoonShiong Many of your companies are already involved: Healthcare Service Provider (NantHealth) Patient Monitoring (Airstrip Keyssa Nantmobile) Networks Data-Center (Mox Networks Packetfabric Serverfarm NantCloud) Will you suggest these companies to CMS $IBRX Finally an administration that understands the real world needs and taking real action to integrate technology to fix our broken health care system. Should have been done decades ago. but it's here now. We are in https://t.co/yEMaAiCtaz Finally an administration that understands the real world needs and taking real action to"
X Link 2025-07-26T18:57Z [--] followers, [---] engagements

"$IBRX Neuralink Integration with ANKTIVA for Revolutionary Immunotherapy @elonmusk a visionary collaboration opportunity by Dr. Sarabi and Grok. Dear Mr Musk: Good morning sir I would like to bring to your attention the remarkable work of Dr. Patrick Soon-Shiong who has developed https://t.co/HcEhO41kIi Neuralink Integration with ANKTIVA for Revolutionary Immunotherapy @elonmusk a visionary collaboration opportunity by Dr. Sarabi and Grok. Dear Mr Musk: Good morning sir I would like to bring to your attention the remarkable work of Dr. Patrick Soon-Shiong who has developed"
X Link 2025-07-27T19:59Z [--] followers, [----] engagements

"Congratulations Information is available in my previous post. NantIQ is a trademark of NantHealth not a specific product. $IBRX https://x.com/MK2forU/status/1949182313696248243 Honored to participate in the initiative by CMS to Make Health Tech Great Again through NantIQ to launch the AI patient centered app to provide Americans access to their health records anytime anyplace across the healthcare system. Patient empowerment w AI @CMSGov @DrOzCMS https://t.co/kJbPGRTjrs https://x.com/MK2forU/status/1949182313696248243 Honored to participate in the initiative by CMS to Make Health Tech Great"
X Link 2025-07-30T18:53Z [--] followers, [---] engagements

"Explaining the IT/AI backbone of $IBRX precision medicine. My post from [----]. https://cloud.hoststar.ch/s/T6ikqbNRwwK8JkE Its hard to believe that we shared this video from Nantworks with ATT in [----] Now its a reality. NantIQ ready for launch . coming soon .real time data at point of care at time of need. medical augmented intelligence https://t.co/UTljK000Jv https://cloud.hoststar.ch/s/T6ikqbNRwwK8JkE Its hard to believe that we shared this video from Nantworks with ATT in [----] Now its a reality. NantIQ ready for launch . coming soon .real time data at point of care at time of need. medical"
X Link 2025-07-30T19:40Z [--] followers, [---] engagements

"Glad to hear youre doing well. $IBRX BioShield Round [--] to prevent recurrence of colon cancer 👊🏼.#cancer #coloncancer #immunotherapy #chemo #capecitabine #xeloda #bioshield #immunitybio #cancerdecoded #MAHA #crossfit https://t.co/z2zsW3zmHS BioShield Round [--] to prevent recurrence of colon cancer 👊🏼.#cancer #coloncancer #immunotherapy #chemo #capecitabine #xeloda #bioshield #immunitybio #cancerdecoded #MAHA #crossfit https://t.co/z2zsW3zmHS"
X Link 2025-08-02T05:08Z [--] followers, [---] engagements

"@DrPatSoonShiong's involvement with his @NantHealth in the @CMSGov initiatives supported by leading AI COs will also step up his $IBRX BioShield Platform to prevent Lymphopenia in cancer and set a new standard in immunotherapy. @GoogleAI @OpenAI @MicrosoftAI @Apple"
X Link 2025-08-02T15:29Z [--] followers, [---] engagements

"$IBRX @adamfeuerstein The presentation is online now: https://cattendee.abstractsonline.com/meeting/21151/presentation/3355 @DrPatSoonShiong Dr. Soon-Shiong Can you please post the WCLC poster on the $IBRX website https://cattendee.abstractsonline.com/meeting/21151/presentation/3355 @DrPatSoonShiong Dr. Soon-Shiong Can you please post the WCLC poster on the $IBRX website"
X Link 2025-09-07T19:45Z [---] followers, [----] engagements

"@DavidDin @DrPatSoonShiong Thank you David for sharing this incredible story. Let us hope that the components of the NANT Cancer vaccine will soon contribute to the fight against cancer and infectious diseases regardless of whether a Nobel Prize is upcoming or not"
X Link 2025-09-09T19:42Z [---] followers, [--] engagements

"$IBRX Orchestration of the Bioshield platform Outsmart the tumor Connecting the dots The distinction between liquid and solid tumors matters Democratizing Cell Therapy https://cancerworld.net/patrick-soon-shiong-he-who-speaks-for-the-people/print=pdf https://cancerworld.net/patrick-soon-shiong-he-who-speaks-for-the-people/print=pdf"
X Link 2025-09-10T17:41Z [---] followers, [---] engagements

"$IBRX https://x.com/DrPatSoonShiong/status/1966964945402421745 @DrPatSoonShiong Many of your companies are already involved: Healthcare Service Provider (NantHealth) Patient Monitoring (Airstrip Keyssa Nantmobile) Networks Data-Center (Mox Networks Packetfabric Serverfarm NantCloud) Will you suggest these companies to CMS $IBRX https://t.co/Xccx0IACQ7 https://x.com/DrPatSoonShiong/status/1966964945402421745 @DrPatSoonShiong Many of your companies are already involved: Healthcare Service Provider (NantHealth) Patient Monitoring (Airstrip Keyssa Nantmobile) Networks Data-Center (Mox Networks"
X Link 2025-09-14T14:55Z [---] followers, [---] engagements

"SITC [--] abstract [---] will showcase a new combination therapy for prostate cancer: ATR inhibitor Tuvusertib (EMD Serono/Merck Group) paired with IL-15 superagonist Anktiva (ImmunityBio). @sitcancer @merckgroup $IBRX #SITC2025 #Immunotherapy #Interleukin15 https://www.sitcancer.org/2025/abstracts/titles-and-publicationsSITC%202025%20Abstracts%5Bquery%5D=N-803 https://www.sitcancer.org/2025/abstracts/titles-and-publicationsSITC%202025%20Abstracts%5Bquery%5D=N-803"
X Link 2025-10-08T10:03Z [---] followers, [----] engagements

"$IBRX BioShield platform what's next Consider a regulatory disruption to a Bioshield Master IND platform a ligand-driven modular immunopatform and what should be done now @ImmunityBio @DrPatSoonShiong https://cloud.hoststar.ch/s/zww7Qd3x2YMxM4A https://cloud.hoststar.ch/s/zww7Qd3x2YMxM4A"
X Link 2025-07-15T15:04Z [---] followers, [----] engagements

"$IBRX U.S.-Saudi Investment Forum November [--] [----] Kennedy Center Washington https://saudi-usinvestmentforum.com/home/ https://saudi-usinvestmentforum.com/home/"
X Link 2025-11-14T08:09Z [---] followers, 11K engagements

"$IBRX @DrPatSoonShiong Yes please but also take responsibility for navigating the regulatory process with a BioShield platform. With the new plausible mechanism pathway you can complete it in about 2-3 years. Its 100% feasible. Facts: https://tinyurl.com/437xrx77 So this is what 10000+ requests from patients and family looks like. Every page is a single request. Our clinic is desperately trying to respond to every single query. I'm afraid this will get worse once the special airs on TV next week. I'm thinking of establishing a Cancer https://t.co/e1xJjoz3IH https://tinyurl.com/437xrx77 So"
X Link 2025-11-17T09:21Z [---] followers, [----] engagements

"$IBRX EU partner"
X Link 2025-11-17T20:22Z [---] followers, [----] engagements

"$IBRX LONG-COVID INTERRUPT_LC trial (NCT07108036 Phase II): During PolyBios fall [----] symposium Dr. Michael Peluso announced that the recruiting process would begin before Thanksgiving. 6:15:31: Supporting the immune response in Long COVID: INTERRUPT-LC https://www.youtube.com/watchv=dGbb7UDcoHw Dr. Peluso wraps-up the #polybiofallsymposium2025 by presenting INTERRUPT-LC a trial of the IL-15 agonist Anktiva. Improving coordination between T-cells and NK cells may lead to better clearing of the virus in Long Covid patients who have persistent viral antigens or whole https://t.co/Htrmw2BtBO"
X Link 2025-11-18T10:02Z [---] followers, [----] engagements

"I hope the top leaders of the SA health delegation set a precedent for a paradigm shift in cancer treatment by backing the Bioshield platform. $IBRX $IBRX U.S.-Saudi Investment Forum November [--] [----] Kennedy Center Washington https://t.co/EYTA7JQ7oD https://t.co/53bws8sqBi $IBRX U.S.-Saudi Investment Forum November [--] [----] Kennedy Center Washington https://t.co/EYTA7JQ7oD https://t.co/53bws8sqBi"
X Link 2025-11-18T17:24Z [---] followers, [----] engagements

"$IBRX This could be a turning point avoiding lymphodepletion caused by standard chemotherapy and radiation. It would be a significant step forward for the entire world to back up the BioShield platform. $IBRX U.S.-Saudi Investment Forum November [--] [----] Kennedy Center Washington https://t.co/EYTA7JQ7oD https://t.co/53bws8sqBi $IBRX U.S.-Saudi Investment Forum November [--] [----] Kennedy Center Washington https://t.co/EYTA7JQ7oD https://t.co/53bws8sqBi"
X Link 2025-11-18T17:26Z [---] followers, [----] engagements

"$IBRX The four partners who underwrote the MOU in May are all speakers at the roundtable; this is no coincidence. https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/ https://immunitybio.com/immunitybio-saudi-arabias-ministry-of-investment-kfshrc-and-kaimrc-sign-strategic-memorandum-of-understanding-to-launch-cancer-bioshieldtm-platform-in-the-middle-east/"
X Link 2025-11-19T08:08Z [---] followers, [----] engagements

"$IBRX The impact of the Saudi Arabia-ImmunityBio agreement from an investment point. https://www.ainvest.com/news/immuno-revolution-desert-immunitybio-saudi-pact-usher-era-cancer-care-profits-2505/ https://www.ainvest.com/news/immuno-revolution-desert-immunitybio-saudi-pact-usher-era-cancer-care-profits-2505/"
X Link 2025-11-19T08:20Z [---] followers, [----] engagements

"@wafflesnspace @pdsandiego If a contract was signed we will hear from Saudi Arabia"
X Link 2025-11-19T19:21Z [---] followers, [--] engagements

"$IBRX During the USSaudi Investment Forum [----] #KAIMRC signed a strategic collaboration with #ImmunityBio to localize advanced cell-therapy technologies for hard-to-treat cancers and advance AI-driven innovation in healthcare. The partnerships uniqueness lies in combining KAIMRCs https://t.co/y6W22PwqYO During the USSaudi Investment Forum [----] #KAIMRC signed a strategic collaboration with #ImmunityBio to localize advanced cell-therapy technologies for hard-to-treat cancers and advance AI-driven innovation in healthcare. The partnerships uniqueness lies in combining KAIMRCs"
X Link 2025-11-21T22:31Z [---] followers, [----] engagements

"$IBRX Anktiva and the patents to overcome the primary driver of Immunosuppression. #Anktiva #Immunotherapy #PrecisionMedicine https://cloud.hoststar.ch/s/q4RLD5ae9ZNLTCd https://cloud.hoststar.ch/s/q4RLD5ae9ZNLTCd"
X Link 2025-11-25T19:41Z [---] followers, [----] engagements

"$IBRX Your points are correct but reducing Bioshield to IL-15 is incorrect and your conclusions are wrong. Bioshield is a protocol and IL-15 is just one component among many. 1) Review the patent that underpins Bioshield. https://patentscope.wipo.int/search/en/detail.jsfdocId=US421386845&_cid=P22-LSK32X-71056-1 ⚠Why Treating #ALC With IL-15 Does Not Cure Cancer And why the $IBRX BioShield thesis collapses in the face of immunology clinical evidence and $NWBO #DCVax biology #Lymphopenia is a recognized diagnosis. It has an ICD code. But treating absolute lymphocyte count (ALC) as if"
X Link 2025-11-29T09:19Z [---] followers, [----] engagements

"$IBRX 2) Then listen to @DrPatSoonShiong explaining the concept of the Bioshield protocol (formerly Nant Cancer Vaccine) in [----]. https://www.youtube.com/watchv=MgnGrUjVmOE ⚠Why Treating #ALC With IL-15 Does Not Cure Cancer And why the $IBRX BioShield thesis collapses in the face of immunology clinical evidence and $NWBO #DCVax biology #Lymphopenia is a recognized diagnosis. It has an ICD code. But treating absolute lymphocyte count (ALC) as if https://t.co/bUj4qkym2J https://www.youtube.com/watchv=MgnGrUjVmOE ⚠Why Treating #ALC With IL-15 Does Not Cure Cancer And why the $IBRX BioShield"
X Link 2025-11-29T09:21Z [---] followers, [----] engagements

"$IBRX 3) Check out my [----] overview of the concrete platforms supporting the Bioshield protocol with hundreds of patents. I will soon release an updated version explaining the bioshield protocol in detail. https://optionicity.com/biotech/ibrx/platform.shtml ⚠Why Treating #ALC With IL-15 Does Not Cure Cancer And why the $IBRX BioShield thesis collapses in the face of immunology clinical evidence and $NWBO #DCVax biology #Lymphopenia is a recognized diagnosis. It has an ICD code. But treating absolute lymphocyte count (ALC) as if https://t.co/bUj4qkym2J"
X Link 2025-11-29T09:23Z [---] followers, [----] engagements

"4) An example of a Bioshield success protocol explained by @GretchMick in her fight against colon cancer. $IBRX https://x.com/GretchMick/status/1960057489828766049 Post Bioshield Test Results #cancersurveillance #cancer #coloncancer #chemo #bioshield $IBRX @ImmunityBio @CCAlliance https://t.co/LpEXPqTswt https://x.com/GretchMick/status/1960057489828766049 Post Bioshield Test Results #cancersurveillance #cancer #coloncancer #chemo #bioshield $IBRX @ImmunityBio @CCAlliance https://t.co/LpEXPqTswt"
X Link 2025-11-29T09:58Z [---] followers, [----] engagements

"$IBRX Your points have been received. Since I dont have a premium account my reply is attached. @MK2forU @GretchMick The colon-cancer example doesnt actually show BioShield working. It shows the limits of what BioShield is built on. Every component in that regimen depends on mechanisms that colon tumors shut down very effectively. Anktiva (IL-15) IL-15 can raise NK and T-cell numbers but @MK2forU @GretchMick The colon-cancer example doesnt actually show BioShield working. It shows the limits of what BioShield is built on. Every component in that regimen depends on mechanisms that colon tumors"
X Link 2025-11-29T19:26Z [---] followers, [---] engagements

"$IBRX Andrew you are completely mistaken. The media snippet provides a brief answer. A detailed response addressing your claims can be found in the linked PDF. https://cloud.hoststar.ch/s/qLi5MW4D2Azb2Nk @MK2forU Those platform slides actually prove my point. A long list of technologies does not create an immune-instruction system. The $IBRX #BioShield ecosystem is built from modules CAR-NK viral-vector vaccines immunocytokines fusion proteins but each of those pieces still depends https://cloud.hoststar.ch/s/qLi5MW4D2Azb2Nk @MK2forU Those platform slides actually prove my point. A long list"
X Link 2025-11-30T12:53Z [---] followers, [---] engagements

"$IBRX Anktiva demonstrates the strongest 36-month signals for bladder preservation and disease-specific survival in Papillary NMBIC. This prospective registrational data support an sBLA. https://www.auajournals.org/doi/10.1097/JU.0000000000004782 https://www.auajournals.org/doi/10.1097/JU.0000000000004782"
X Link 2025-12-04T14:18Z [---] followers, [----] engagements

"@MayoClinic @Harvardmed and @Penn_MSHP all report risks related to low ALC in CAR-T therapy. Read my post about Anktiva in recovering ALC after CAR-T cell therapy and how NK-cell lysate could be helpful before or during CAR-T cell therapy. $IBRX https://cloud.hoststar.ch/s/aecHWe5LXSaJB68 https://cloud.hoststar.ch/s/aecHWe5LXSaJB68"
X Link 2025-12-08T10:32Z [---] followers, [---] engagements

"$IBRX Now it begins to get interesting. https://x.com/MK2forU/status/1950642698031153220 Most AI in medicine analyzes data. Few predicts disease dynamics. None plan and route treatment through the tumor microenvironment. That category -biological autonomy- did not exist. Now it does. #Biotech #DigitalTwin #DeepTech https://x.com/MK2forU/status/1950642698031153220 Most AI in medicine analyzes data. Few predicts disease dynamics. None plan and route treatment through the tumor microenvironment. That category -biological autonomy- did not exist. Now it does. #Biotech #DigitalTwin #DeepTech"
X Link 2025-12-11T15:17Z [---] followers, [---] engagements

"$IBRX The evidence of radiotherapy-induced lymphopenia (RIL) is clear; it hampers the effectiveness of subsequent immune checkpoint therapy. IL-15 (Anktiva) is mentioned as a solution to this problem. We dont need more papers. Approve ANKTIVA for Lymphopenia"
X Link 2025-12-17T11:14Z [---] followers, [----] engagements

"$IBRX Chemotherapy-induced lymphopenia (CIL) is a significant side effect of chemo. When chemo and radiation are combined 100% of patients develop lymphopenia. For years the severe impacts have been known. We dont need more papers. Approve ANKTIVA for lymphopenia now"
X Link 2025-12-20T19:45Z [---] followers, [----] engagements

"$IBRX Remember elephants have no cancer due to several p53 variants. Now Anktiva can help fight prostate cancer by boosting NK-cell-mediated lysis of p53-mutant cancer cells while Tuvusertib (Merck) targets the tumor. https://pubmed.ncbi.nlm.nih.gov/41417226/ https://pubmed.ncbi.nlm.nih.gov/41417226/"
X Link 2025-12-23T17:04Z [---] followers, [----] engagements

"$IBRX If you want more background on the Nantworks companies in Biotech IT/AI and Healthcare especially regarding the Cancer Bioshield visit my blog at https://cloud.hoststar.ch/s/mqXXogaS996NBkN Will be an exciting JPM week. Will be co chairing the Inaugural USA Saudi Biotech Alliance with senior decision makers flying in to an exciting all day event. @ImmunityBio Nantworks reveal biotechs and bankers. More to come. https://cloud.hoststar.ch/s/mqXXogaS996NBkN Will be an exciting JPM week. Will be co chairing the Inaugural USA Saudi Biotech Alliance with senior decision makers flying in to an"
X Link 2026-01-09T12:24Z [---] followers, [----] engagements

"The new apheresis platform will be based on the experience with the Nant-O01 automated bioreactor from Vivabiocell a wholly owned subsidiary of $IBRX and on contributions from Sang Yoon who previously served as the product developer for ALYX apheresis devices"
X Link 2026-01-10T20:17Z [---] followers, 14K engagements

"$IBRX Sang Yoon brings 25+ years of global experience across biologics medical devices. From Baxter to Samsung Biologics and now ImmunityBio his journey is a masterclass in leadership. https://www.youtube.com/watchv=gO7q-XF-FBM The new apheresis platform will be based on the experience with the Nant-O01 automated bioreactor from Vivabiocell a wholly owned subsidiary of $IBRX and on contributions from Sang Yoon who previously served as the product developer for ALYX apheresis devices. https://t.co/6XAZAlIH3x https://www.youtube.com/watchv=gO7q-XF-FBM The new apheresis platform will be based on"
X Link 2026-01-10T20:20Z [---] followers, [----] engagements

"$IBRX The official comprehensive description of the Cancer Bioshield Multi-Modal Immunotherapy platform. https://immunitybio.com/platforms/ https://immunitybio.com/platforms/"
X Link 2026-01-11T09:57Z [---] followers, [----] engagements

"$IBRX The upcoming apheresis bioreactor announced next week will revolutionize cell therapy serve as a key milestone for the apheresis platform and most importantly benefit M-ceNK and add Apheresis to the Cancer Bioshield platform. Link to my table: https://cloud.hoststar.ch/s/wXHCYHgzpwpD37p https://cloud.hoststar.ch/s/wXHCYHgzpwpD37p"
X Link 2026-01-11T16:11Z [---] followers, 11K engagements

"The impact of the new FDA requirements on the $IBRX apheresis platform. https://www.reddit.com/r/IBRX/comments/1qawze4/fda_increases_flexibility_on_requirements_for/ $IBRX The upcoming apheresis bioreactor announced next week will revolutionize cell therapy serve as a key milestone for the apheresis platform and most importantly benefit M-ceNK and add Apheresis to the Cancer Bioshield platform. Link to my table: https://t.co/C3aBga8RMk https://t.co/T3nzP41jvK https://www.reddit.com/r/IBRX/comments/1qawze4/fda_increases_flexibility_on_requirements_for/ $IBRX The upcoming apheresis bioreactor"
X Link 2026-01-12T15:18Z [---] followers, [----] engagements

"$IBRX Combining the apheresis machine with NK-cell lysis can enhance tumor targeting. Using lysed (dead) m-ceNK cells after apheresis provides a tumor-killing mechanism that bypasses tumor resistance and reduces off-target effects. IMO incredible opportunities open up there. $IBRX How the Natural Killer cell lysate reduces the damage caused by Lymphodepletion in T-cell therapies. #Immunotherapy @ImmunityBio https://t.co/Nix2srKp38 https://t.co/NHdfbjKMEx $IBRX How the Natural Killer cell lysate reduces the damage caused by Lymphodepletion in T-cell therapies. #Immunotherapy @ImmunityBio"
X Link 2026-01-13T17:17Z [---] followers, [----] engagements

"Reliance on chemotherapy radiation and T-cells alone wont sufficiently address cancer. The key is to integrate the Cancer Bioshield combining NK- and T-cells both natural immune defenders and to boost them with Anktiva. $IBRX https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01570-3/abstract https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01570-3/abstract"
X Link 2026-01-14T16:27Z [---] followers, [----] engagements

"$IBRX ImmunityBioss CAR-NK platform is currently not the main focus but it is expected to become the most significant platform in the future. Read my post here: https://cloud.hoststar.ch/s/PZN33q42ip8HMcr https://cloud.hoststar.ch/s/PZN33q42ip8HMcr"
X Link 2026-01-15T10:24Z [---] followers, [----] engagements

"$IBRX @SandyGl88167783 Is there anyone here who can help get Sandys daughter into the BioShield program @DrPatrick @ImmunityBio @DrMakaryFDA @GretchMick @MK2forU Rejected her because she still can do chemo which is ridiculous because she needs to fortify her immune system during treatment. Oncologist filed an appeal @MK2forU Rejected her because she still can do chemo which is ridiculous because she needs to fortify her immune system during treatment. Oncologist filed an appeal"
X Link 2026-01-15T15:55Z [---] followers, [----] engagements

"$IBRX @DeanJC420 Good to hear about your good results with Anktiva. All the best and keep fighting Please continue to share your experiences with us. Thank you $IBRX I learned about this company after my cancer diagnosis. I consider the work being done with immunology to be hopeful for cancer patients like me. The clinical testing is advancing with some good results and uptake of the Anktiva medicine. "SAUDI FDA GRANTS ACCELERATED https://t.co/zfvDGXASdO $IBRX I learned about this company after my cancer diagnosis. I consider the work being done with immunology to be hopeful for cancer"
X Link 2026-01-15T16:51Z [---] followers, [----] engagements

"$IBRX @DeanJC420 Sorry I misunderstood you. We need to fight to ensure everyone can access Anktiva. @MK2forU I wish I were in one of the trials but I so far have failed to apply for access. I know that the first night I learned I had cancer in June [----] I got to work learning what kind of cures might be out there. Anktiva is one of my hopes for me and for everyone. The results are @MK2forU I wish I were in one of the trials but I so far have failed to apply for access. I know that the first night I learned I had cancer in June [----] I got to work learning what kind of cures might be out there."
X Link 2026-01-15T17:27Z [---] followers, [----] engagements

"$IBRX More details on CD-19 t-haNK and a summary of the ImmunityBios CAR-NK platform. https://cloud.hoststar.ch/s/PZN33q42ip8HMcr Tomorrow will announce data on COMPLETE REMISSION now lasting [--] months and ongoing in patients with lymphoma receiving chemo therapy free CD19 Car NK cell therapy. Response after just [--] doses and a total of [--] doses with no further treatment To scale we need AI driven robots . https://cloud.hoststar.ch/s/PZN33q42ip8HMcr Tomorrow will announce data on COMPLETE REMISSION now lasting [--] months and ongoing in patients with lymphoma receiving chemo therapy free CD19 Car"
X Link 2026-01-16T06:31Z [---] followers, [----] engagements

"@ccs648 Shorts are currently underwater but havent closed their positions yet. They believe the stock is overvalued and may start shorting it from this high level. A decline could happen quickly as many inexperienced shareholders might sell rather than hold through the attack"
X Link 2026-01-20T16:15Z [---] followers, [---] engagements

"Thank you for your fight for #ChildhoodCancer your support and your expert assessment of @DrPatrick and his Immunotherapy [---]. $IBRX A leading force in cancer innovation is making real strides. Dr. Patrick Soon-Shiong & ImmunityBio are powering ahead with Anktiva a groundbreaking IL-15 superagonist immunotherapy that activates & multiplies the bodys natural killer (NK) cells & memory T cells to precisely https://t.co/0Kte3T5C16 A leading force in cancer innovation is making real strides. Dr. Patrick Soon-Shiong & ImmunityBio are powering ahead with Anktiva a groundbreaking IL-15 superagonist"
X Link 2026-01-19T07:42Z [---] followers, [----] engagements

"$IBRX Exactly more details on PF-L1 t-haNK and my summary of the ImmunityBios CAR-NK platform. https://cloud.hoststar.ch/s/PZN33q42ip8HMcr This is huge for oncology building on Anktiva's IL-15 boost to supercharge those engineered CAR-NK cells against cancer. The PD-L1 targeting in early studies already showed promise in lysing tumors & hitting MDSCs & with Phase [--] underway [----] could mark a real shift in off the https://cloud.hoststar.ch/s/PZN33q42ip8HMcr This is huge for oncology building on Anktiva's IL-15 boost to supercharge those engineered CAR-NK cells against cancer. The PD-L1"
X Link 2026-01-19T07:49Z [---] followers, [----] engagements

"Study details: https://clinicaltrials.gov/study/NCT07108036 https://clinicaltrials.gov/study/NCT07108036"
X Link 2026-02-01T12:25Z [---] followers, [---] engagements

"Cancer Bioshield [---] for all cancer types with high TGF- burden. @ImmunityBio just filed a patent for a TGF-trap (US20250195614). $IBRX HCW9218 is already in a Phase I/II trial for advanced pancreatic cancer (NCT05304936) and would integrate well into the Cancer Bioshield"
X Link 2025-06-30T16:07Z [---] followers, [----] engagements

"$IBRX How the Natural Killer cell lysate reduces the damage caused by Lymphodepletion in T-cell therapies. #Immunotherapy @ImmunityBio https://cloud.hoststar.ch/s/aecHWe5LXSaJB68 https://cloud.hoststar.ch/s/aecHWe5LXSaJB68"
X Link 2025-11-09T20:27Z [---] followers, [----] engagements

"At present $IBRX has significant synthetic short positions. Could this position it as a prime candidate for a short squeeze"
X Link 2026-01-13T15:45Z [---] followers, 13.2K engagements

"$IBRX ImmunityBios Apheresis Platform https://cloud.hoststar.ch/s/AZttTSkwAWLpmYQ Revealed at our summit: building and teaching with machine vision and AI the worlds first robot to manufacture NK cells at scaleWill be installed in next [--] months and then we change the cost of cell therapy forever to make it available to so many who need immune restoration https://t.co/Qc6Mfd0c8g https://cloud.hoststar.ch/s/AZttTSkwAWLpmYQ Revealed at our summit: building and teaching with machine vision and AI the worlds first robot to manufacture NK cells at scaleWill be installed in next [--] months and then we"
X Link 2026-01-16T08:22Z [---] followers, [----] engagements

"I told you so. 👊 $IBRX At present $IBRX has significant synthetic short positions. Could this position it as a prime candidate for a short squeeze https://t.co/OZKk2NiUcd At present $IBRX has significant synthetic short positions. Could this position it as a prime candidate for a short squeeze https://t.co/OZKk2NiUcd"
X Link 2026-01-20T15:46Z [---] followers, [----] engagements

"$IBRX Papillary"
X Link 2026-01-20T18:41Z [---] followers, [----] engagements

"$IBRX Latest borrow rate 43% really"
X Link 2026-01-21T18:50Z [---] followers, 16.1K engagements

"$IBRX Now at 75% and with zero shares to attack. With the intention of who to attack Cancer patients waiting for a cure with less chemo and less radiation $IBRX Latest borrow rate 43% really https://t.co/aueCvAlJsa $IBRX Latest borrow rate 43% really https://t.co/aueCvAlJsa"
X Link 2026-01-23T14:42Z [---] followers, 16.8K engagements

"Apheresis platform: Yesterday $IBRX announced a new M-ceNK patent for a process that boosts B cells NK cells and dendritic cells and elevates CD16/CD56 expression to expand cancer targeting. https://patentscope.wipo.int/search/en/detail.jsfdocId=WO2026024752&_cid=P21-MKZU9I-06927-1 https://patentscope.wipo.int/search/en/detail.jsfdocId=WO2026024752&_cid=P21-MKZU9I-06927-1"
X Link 2026-01-30T09:02Z [---] followers, [----] engagements

"$IBRX Lysing expanded NK cells after apheresis preserves beneficial components and reduces side effects. NK cell lysates can be injected into tumors avoiding rejection and adverse effects of live cells. Countless new opportunities are emerging $IBRX How the Natural Killer cell lysate reduces the damage caused by Lymphodepletion in T-cell therapies. #Immunotherapy @ImmunityBio https://t.co/Nix2srKp38 https://t.co/NHdfbjKMEx $IBRX How the Natural Killer cell lysate reduces the damage caused by Lymphodepletion in T-cell therapies. #Immunotherapy @ImmunityBio https://t.co/Nix2srKp38"
X Link 2026-01-31T07:58Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing